DIA Singapore Annual Meeting 2019
- CEO (Asia Pacific), AIME Inc. USA
- AIME, Malaysia, Malaysia
Helmi Zakariah, MD, is CEO for AIME INC operations in Malaysia and Asia Pacific. Dr. Zakariah previously served in the Malaysia Ministry of Health, co-founding the Global Health Division which strategizes, coordinates, and oversees Malaysia engagement with global health entities such as the World Health Organization and ASEAN Health Secretariat. He first engaged in public health as a program manager for National Tuberculosis Control Programme, where he established a new screening algorithm still in use statewide, and served on the 2014 Joint United Nations Initiative for Migration in Asia Steering Committee. Dr. Zakariah earned his Medical Degree from the Russian Federation, and Masters’ Degree in International Public Health from Liverpool.
Angelika Joos, MPharm
- Executive Director, Global Regulatory Policy
- Merck Sharp & Dohme (Europe) Inc., Belgium
Angelika Joos, MPharm, is responsible for Regulatory Policy issues within MSD's Global Regulatory Affairs and Clinical Safety department. This role includes identifying regulatory policy priorities that align with MSD’s business priorities, leading cross-functional networks to define policy positions, and informing MSD’s regulatory strategy development. Angelika represents MSD in various Committees of the European Federation of Pharmaceutical Manufacturers and Associations, EuropaBio, and the European Confederation of Pharmaceutical Entrepreneurs; she is also involved in international policy activities as the MSD delegate in the IFPMA Regulatory Science Committee, and the BIO and the PhRMA international Committees.
- Area Vice President for Professional Services
- Medidata Solutions , China
Gau Churn-Shiouh, DrSc
- Office Director
- Project Office of Sustainable Platform For Big Data In Health By MOHW, Ching-Kan, Taiwan
Dr. Churn-Shiouh Gau is the Executive Director of Center for Drug Evaluation, Taiwan and the adjunct professor of School of Pharmacy, National Taiwan University. She has more than 20 years experience on drug evaluation specialized in CMC. She was the project leader for the establishing of national pharmacovigilance of Taiwan. Dr. Gau has published more that 50 research papers in the areas of drug safety, pharmacoepidemiology, and pharmaceutics.
- Regional Business Leader
- Microsoft Asia, Singapore
As Regional Business Lead of Worldwide Health for Microsoft Asia, Dr. Keren Priyadarshini leads the company’s healthcare business segment across 17 markets in Asia Pacific. Dr. Priyadarshini is responsible for driving and implementing Microsoft’s healthcare initiatives across the region as well as developing solution offerings and strategies that meet the needs of healthcare and life science customers. She also plays a leading role in establishing thought leadership by defining and articulating the company’s vision for the future of healthcare and sharing how Microsoft technologies and partner solutions are making it a reality.
Chng Wee Joo
- National University Cancer Institute, Singapore
Shimon Yoshida, PhD
- Executive Director, International Labeling Group, Global Regulatory Affairs
- Pfizer Inc, United Kingdom
Dr Shimon Yoshida is Executive Director at Pfizer, and heads the International Labeling Group in Global Regulatory Affairs. Dr Yoshida obtained a PhD in Chemistry from Reading University, UK, and held postdoctoral positions at Durham University before joining the Royal Society of Chemistry in Cambridge. After joining Pfizer in 1999 he worked in a variety of roles across pharmacovigilance, medical writing, safety, and labeling, and is currently leading Pfizer’s global digital innovation project to transform Regulatory Operations processes.